IHC validation demonstrated increased expression of the M1 markers iNOS, IL-1β, as well as the M2 marker CD163, in SAMD9high glioblastoma tissues relative to SAMD9low tissues (Fig. 6g, h). This evidence concerns the gene IL1B and glioblastoma.